Spectrum Pharmaceuticals (NasdaqGS: SPPI) announced the initiation of a Phase 2 trial of ZEVALIN for intravenous use + rituximab in combination with motexafin gadolinium (MGd) in patients with rituximab-refractory low-grade or follicular B-cell non-Hodgkin’s lymphoma (NHL).
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced efficacy and safety results from its Phase 2 trial of urocortin 2 in 53 patients with acute decompensated heart failure. Mean arterial pressures were significantly reduced (p<0.001) from 92 +/- 3 mmHg at baseline to 80+/-3 mmHg at end of the urocortin 2 infusion (n=27) in contrast to placebo (n=26) where the mean arterial pressure was 92 +/- 3 mmHg at baseline and 89 +/- 4 mmHg at the end of the placebo infusion. Heart rates were slightly higher during urocortin 2 infusion than placebo although these remained in normal range and comparable in both groups post infusion. In the subset of subjects undergoing right heart catheterization (n=20, 10 per arm), cardiac output increased markedly by over 50% in those randomized to urocortin 2 compared to unchanging values in the placebo group (p=0.003). The company will require a partner for further development.
NovaBay Pharmaceuticals, Inc. (NYSE AMEX: NBY) announced that it has commenced enrolment in a Phase 2b trial named BAYnovationTM, evaluating NVC-422, for the treatment of adenoviral conjunctivitis. Top-line data are expected in 1H 2013. It also noted that a Phase 2b trial of NVC-422 for the treatment of highly contagious skin infection, impetigo, is planned for 2012. Also, top-line results from Part B of its Phase 2b trial of NVC-422 for patients with urinary catheter blockage and encrustation (UCBE), are expected later in 2012.